Farxiga Cost in Kentucky 2026: Cash Price, Medicaid, and Compounded Dapagliflozin Options

What Does Farxiga Actually Cost in Kentucky Right Now?

The manufacturer's list price for Farxiga sits at approximately $620 per 30-day supply in 2026, and that figure does not change meaningfully from one Kentucky retail chain to another. CVS, Walgreens, and independent pharmacies in Louisville, Lexington, and Bowling Green all land within a few dollars of that number for the brand-name tablet. What changes the real out-of-pocket figure is the patient's insurance status, eligibility for manufacturer assistance, and whether a compounded alternative is appropriate.

AstraZeneca sets the wholesale acquisition cost (WAC) for dapagliflozin 10 mg at around $620/month. That price has increased modestly year over year since the drug's 2014 FDA approval for type 2 diabetes, with subsequent approvals for heart failure with reduced ejection fraction (HFrEF) in 2020 and chronic kidney disease (CKD) in 2021 pushing demand higher. Because no generic dapagliflozin has received FDA approval as of mid-2025, the brand-name price has no generic floor in the U.S. market.

GoodRx and similar coupon platforms can bring the cash price at some Kentucky pharmacies to the $580 to $610 range, a savings of roughly 3 to 6 percent. That margin is narrow. Patients paying entirely out of pocket should pursue the manufacturer savings card or telehealth-linked compounding before relying on coupon platforms alone.

Farxiga FDA label and approval history

Does Kentucky Medicaid Cover Farxiga?

Kentucky Medicaid does not cover Farxiga for the vast majority of beneficiaries. The state's preferred drug list (PDL) for both Kentucky Medicaid and the Kentucky Children's Health Insurance Program (KCHIP) places brand-name SGLT2 inhibitors in a non-preferred or excluded tier for most clinical indications, meaning prior authorization requests are routinely denied without an exceptional clinical justification.

This is a real financial gap for a state that ranks among the highest in the U.S. for both type 2 diabetes prevalence and heart failure hospitalizations. The CDC reports that 13.9% of Kentucky adults had diagnosed diabetes in 2023, compared to the national average of 11.6% [1]. Patients who need an SGLT2 inhibitor for CKD-related cardiometabolic protection and who rely on Medicaid face the steepest access barriers.

Managed care organizations (MCOs) that administer Kentucky Medicaid benefits, including Anthem, Humana CommunityPlan, Molina, and WellCare, may each carry slightly different formulary rules. Patients covered through one of these MCOs should confirm formulary status directly with the plan, because individual MCO formularies occasionally differ from the state PDL on branded medications. A prescribing clinician can submit a prior authorization request citing the 2022 ADA/KDIGO joint consensus statement on CKD management, which recommends SGLT2 inhibitors as first-line therapy for patients with type 2 diabetes and CKD [2].

Kentucky Medicaid MCO formulary information

Kentucky Private Insurance and Farxiga Formulary Placement

Private insurance coverage in Kentucky varies sharply by plan tier. Most commercial plans (employer-sponsored, ACA marketplace) place Farxiga on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), producing copays between $60 and $200 per month after deductible.

Medicare Part D is a different story. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D enrollees took full effect in 2025. For Kentucky Medicare beneficiaries in the catastrophic phase of coverage, Farxiga costs are subject to that cap, which meaningfully limits total annual exposure for high-utilization patients. Standard Part D plans in Kentucky typically place dapagliflozin on Tier 3 or Tier 4 with negotiated costs ranging from $45 to $110 per month depending on plan and phase of coverage.

Patients with commercial insurance should verify whether their specific plan accepts the AstraZeneca savings card (see section below), because some high-deductible health plans and all federal insurance programs (Medicare, Medicaid, TRICARE) are explicitly excluded from manufacturer coupon programs under federal anti-kickback statute guidance.

2023 ADA Standards of Care in Diabetes

The AstraZeneca Savings Card: How It Works for Kentucky Patients

AstraZeneca operates a patient savings program for Farxiga that can reduce monthly cost to $10 for eligible commercially insured patients and to $0 for uninsured or underinsured patients who meet income criteria. The program is called the AstraZeneca Patient Assistance Program (PAP) for those without insurance, and the Farxiga Savings Card for commercially insured patients.

For the savings card:

• Eligible patients must have commercial insurance (no Medicare, Medicaid, or government-funded plans).
• The card reduces copay to as low as $10 per 30-day supply.
• Enrollment is free through AstraZeneca's website or by phone.
• The card may be used at any participating retail pharmacy in Kentucky.
• Income limits apply for the uninsured PAP tier, generally set below 600% of the federal poverty level.

For Kentucky patients without any insurance who do not qualify for the PAP income threshold, the $620 cash price applies unless they access compounding (discussed below) or use a GoodRx-type coupon to shave a marginal amount. The savings card is the single most effective cost-reduction tool for commercially insured Kentucky patients. Clinicians prescribing Farxiga should routinely hand savings-card enrollment information to patients at the point of prescribing.

DAPA-HF trial, NEJM 2019

Why Farxiga Is Prescribed: The Clinical Evidence Behind the Cost

Understanding what Farxiga does clinically helps patients and prescribers decide whether a cost-reduction strategy (savings card, compounding, or formulary switch) is worth pursuing versus switching to an alternative SGLT2 inhibitor with better formulary placement.

Dapagliflozin is an SGLT2 inhibitor that blocks sodium-glucose cotransporter 2 in the kidney, increasing urinary glucose excretion and reducing blood glucose independently of insulin. It carries three distinct FDA-approved indications.

Type 2 diabetes. The DECLARE-TIMI 58 trial (N=17,160) showed dapagliflozin was non-inferior to placebo for major adverse cardiovascular events (MACE) in a broad type 2 diabetes population and produced a significant 27% relative reduction in the composite of cardiovascular death or hospitalization for heart failure [3].

Heart failure. DAPA-HF (N=4,744) demonstrated that dapagliflozin 10 mg once daily reduced the risk of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) in patients with HFrEF, regardless of diabetes status [4]. The authors concluded: "Dapagliflozin reduced the risk of worsening heart failure or death from cardiovascular causes among patients with heart failure and a reduced ejection fraction, with results consistent in patients with and without diabetes." [4]

Chronic kidney disease. DAPA-CKD (N=4,304) showed a 39% relative risk reduction in the composite of sustained 50% decline in eGFR, end-stage kidney disease, cardiovascular death, or renal death (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [5]. The 2022 KDIGO guidelines on CKD management list SGLT2 inhibitors, including dapagliflozin, as a 1A recommendation (strong evidence) for patients with type 2 diabetes, CKD, and eGFR 25 mL/min/1.73 m² or above [2].

These data points matter for Kentucky patients because they support the clinical argument a prescriber can use in a prior authorization appeal to a Medicaid MCO or a resistant commercial insurer. A well-documented prior authorization that cites DAPA-HF or DAPA-CKD trial data and the KDIGO 1A recommendation is substantially more likely to succeed than a generic formulary exception request.

DAPA-CKD, NEJM 2020

Is Compounded Dapagliflozin Legal in Kentucky?

Compounded dapagliflozin is available through licensed 503A compounding pharmacies operating in Kentucky, and prescriptions for it can be written legally by licensed Kentucky clinicians. The short answer: yes, it is legal, provided the pharmacy holds the appropriate state and federal compounding credentials and the prescription is for an identified individual patient.

The legal framework here is worth understanding precisely. Section 503A of the Federal Food, Drug, and Cosmetic Act allows a licensed pharmacist or physician to compound a drug for an individual patient based on a valid prescription, even if a commercially available FDA-approved product exists. This is different from 503B outsourcing facilities, which produce larger batches for healthcare systems. A 503A compound does not require FDA approval of the final product, but the pharmacy must meet state pharmacy board standards, and the compounded product must not be on the FDA's list of drugs that may not be compounded.

As of mid-2025, dapagliflozin is not on the FDA's 503A-prohibited list. Kentucky pharmacies that hold both state board licensure and comply with USP standards for sterile or non-sterile compounding (Farxiga is an oral tablet, so USP 795 applies for non-sterile compounding) may legally compound dapagliflozin for individual patients.

The practical cost difference is significant. Some 503A compounding pharmacies accessible to Kentucky patients (including telehealth-linked pharmacies licensed to dispense in Kentucky) offer compounded dapagliflozin at prices well below the $620 brand-name price point. Cost varies by formulation and pharmacy, but 30-day supplies in the $40 to $150 range are reported in the compounding market.

When compounding may be appropriate:

• Patient meets clinical criteria for dapagliflozin (type 2 diabetes, HFrEF, or CKD with eGFR 25 or above)
• Brand-name Farxiga is unaffordable and the patient does not qualify for the AstraZeneca PAP
• Kentucky Medicaid has denied coverage and appeal options are exhausted
• Prescribing clinician has confirmed no clinically superior formulary alternative (empagliflozin, canagliflozin) exists at lower cost for the patient's specific indication

When to stay with brand-name Farxiga:

• Patient qualifies for the $10 savings card (commercially insured)
• Formulary switch to another SGLT2 inhibitor is clinically equivalent and lower cost
• Patient is enrolled in a clinical trial requiring brand-name drug

One point prescribers must communicate clearly: compounded drugs are not FDA-approved, quality-control processes differ from brand-name manufacturing, and patients should use a pharmacy with clear USP 795 compliance documentation.

FDA 503A compounding guidance

Can a Kentucky Patient Get Farxiga Through Telehealth?

Yes. Kentucky allows telehealth prescribing for Farxiga under state and federal rules as of 2026. A licensed Kentucky clinician can conduct a synchronous (real-time video) or, in some circumstances, asynchronous evaluation and issue a valid prescription for dapagliflozin without an in-person visit, provided the standard of care for diagnosis and prescribing is met.

The 2020 DEA pandemic-era telehealth flexibilities extended broad prescribing access, and Kentucky's state telehealth laws have kept pace. Dapagliflozin is not a controlled substance, which removes the additional layer of DEA regulation that applies to testosterone or stimulants prescribed via telehealth. The prescriber needs to establish a valid patient-provider relationship, document the indication (diabetes, heart failure, or CKD), and send the prescription to a licensed pharmacy in Kentucky.

Telehealth platforms that include compounding pharmacy partnerships may offer the lowest total monthly cost for uninsured Kentucky patients: a telehealth visit fee plus a 503A compounded dapagliflozin prescription. Patients should verify that:

1. The telehealth platform employs clinicians licensed in Kentucky (not just neighboring states).
2. The partner pharmacy is licensed by the Kentucky Board of Pharmacy.
3. The prescription is transmitted to the pharmacy, not dispensed from an unlicensed out-of-state operation.

Kentucky Board of Pharmacy licensing verification

Comparing Dapagliflozin to Other SGLT2 Inhibitors Available in Kentucky

When cost is the primary concern, comparing formulary placement of all FDA-approved SGLT2 inhibitors is worthwhile. Three agents are in widespread clinical use.

Empagliflozin (Jardiance, Boehringer Ingelheim/Lilly). Jardiance holds FDA approval for type 2 diabetes, HFrEF, HFpEF, and CKD. Its WAC is comparable to Farxiga (~$610 to $630/month), but formulary placement varies. Some Kentucky commercial plans tier Jardiance more favorably than Farxiga because of rebate negotiations. The EMPEROR-Reduced trial (N=3,730) showed a 25% relative reduction in cardiovascular death or heart failure hospitalization, comparable to DAPA-HF [6].

Canagliflozin (Invokana, Janssen). Invokana's cash price is also near $600/month. The CREDENCE trial (N=4,401) demonstrated significant renal protection in diabetic nephropathy [7]. Canagliflozin carries a black-box warning for lower-limb amputation risk that dapagliflozin and empagliflozin do not, which influences prescriber choice in patients with peripheral artery disease.

Generic availability. No FDA-approved generic for any SGLT2 inhibitor exists in the U.S. market as of mid-2025. Some patent-expiry projections for dapagliflozin point toward 2029 to 2032 depending on litigation outcomes. Until that window, brand-name pricing or compounding remain the only options.

For Kentucky patients whose commercial plan strongly prefers one agent over another, a therapeutic substitution to the preferred SGLT2 inhibitor with a lower copay may be the most cost-effective path, assuming the indication is equivalent. A prescriber should confirm clinical equivalence before switching.

EMPEROR-Reduced trial, NEJM 2020

Navigating a Farxiga Prior Authorization in Kentucky

A prior authorization (PA) for Farxiga in Kentucky, whether for a Medicaid MCO or a commercial plan, follows a predictable structure. Knowing the required elements in advance speeds approval or strengthens an appeal.

Most Kentucky plans require documentation of:

• Confirmed diagnosis (type 2 diabetes with HbA1c above 7.0%, OR echocardiogram-confirmed HFrEF with LVEF at or below 40%, OR laboratory-confirmed CKD with eGFR 25 to 75 mL/min/1.73 m² and UACR above 200 mg/g)
• Trial-and-failure of metformin for diabetes indications (some plans)
• Documentation that the prescribing clinician reviewed cardiovascular or renal risk factors
• Relevant lab values dated within 6 months

For CKD indications, citing the 2022 KDIGO Clinical Practice Guideline for Diabetes Management in CKD is often decisive. The guideline states: "We recommend treatment with an SGLT2 inhibitor for patients with type 2 diabetes, CKD, and eGFR ≥25 mL/min/1.73 m²." [2] Quoting a 1A guideline recommendation in a PA letter significantly strengthens the case.

If the initial PA is denied, Kentucky patients have the right to an expedited appeal within 72 hours for urgent cases. A prescribing clinician's letter summarizing DAPA-CKD outcomes data and the KDIGO recommendation, submitted with the appeal, constitutes the strongest foundation for overturn.

2022 KDIGO Diabetes Management in CKD guideline

What Dose Do Kentucky Patients Actually Need?

Dapagliflozin is available in 5 mg and 10 mg oral tablets. The dosing depends on indication.

• Type 2 diabetes: 5 mg once daily to start; may increase to 10 mg once daily for additional glycemic or weight benefit. Patients with eGFR <45 mL/min/1.73 m² should not use dapagliflozin for glycemic control alone (insufficient efficacy at low eGFR), though the drug may still be appropriate for cardiorenal indications.
• Heart failure (HFrEF or HFmrEF): 10 mg once daily. This is the dose used in DAPA-HF and the FDA-approved dose for this indication.
• Chronic kidney disease: 10 mg once daily, down to eGFR 25 mL/min/1.73 m² for cardiorenal protection. Do not initiate if eGFR <25 mL/min/1.73 m².

The 30-day supply price at Kentucky pharmacies is the same for both the 5 mg and 10 mg tablets, so dose escalation from 5 mg to 10 mg does not increase monthly medication cost for brand-name Farxiga.

Farxiga full prescribing information via FDA

Kentucky-Specific Cost Summary Table

The following figures reflect 2026 data for Kentucky retail pharmacies and assistance programs.

| Access pathway | Monthly cost (Kentucky) | Eligibility requirement | |---|---|---| | Brand-name Farxiga, cash price | ~$620 | None | | Brand-name Farxiga, GoodRx coupon | ~$580 to $610 | None | | AstraZeneca savings card (commercially insured) | As low as $10 | Commercial insurance, no government plan | | AstraZeneca PAP (uninsured/underinsured) | $0 | Income below ~600% FPL | | Kentucky Medicaid | Not covered | N/A | | Medicare Part D (post-IRA cap) | $45 to $110 | Part D enrollment | | Compounded dapagliflozin (503A pharmacy) | $40 to $150 (varies by pharmacy) | Valid prescription from KY-licensed prescriber |

ADA Standards of Care, cardiovascular section